Anatomy and Cell Biology

Korean Association of Anatomists (대한해부학회)
권호 표지
DOI QR코드

DOI QR Code

$CDH_3$/P-Cadherin regulates migration of $HuCCT_1$ cholangiocarcinoma cells

  • Baek, Sung-Min (Department of Anatomy, School of Medicine, Pusan National University) ;
  • Lee, Yong-Whan (Department of Anatomy, School of Medicine, Pusan National University) ;
  • Yoon, Sik (Department of Anatomy, School of Medicine, Pusan National University) ;
  • Baek, Sun-Yong (Department of Anatomy, School of Medicine, Pusan National University) ;
  • Kim, Bong-Seon (Department of Anatomy, School of Medicine, Pusan National University) ;
  • Oh, Sae-Ock (Department of Anatomy, School of Medicine, Pusan National University)
  • Received : 2010.04.04
  • Accepted : 2010.05.12
  • Published : 2010.06.30
⟨ Previous Next ⟩

Abstract

Intrahepatic cholangiocarcinoma is the second most common subtype of primary hepatobilliary cancer. Despite advances in surgical and medical therapy, its survival rate remains poor. Compared to hepatocellular carcinoma (HCC), the most common liver malignancy, the underlying mechanisms of cholangiocarcinoma carcinogenesis are poorly characterized. P-cadherin (CDH3) is a cadherin super family member. Although CDH3 is frequently over-expressed in cholangiocarcinoma tissues, its roles have never been characterized. To determine the roles of CDH3 in cholangiocarcinoma, we investigated CDH3 function in HuCCT1 cells using specific siRNA. Transfection with CDH3 siRNA did not affect proliferation of HuCCT1 cells. However, cell migration and invasion were significantly reduced when CDH3 was down-regulated. In addition, expressions of several biomarkers for epithelial-mesenchymal transition (EMT) were not changed by CDH3 down-regulation. These results suggest that CDH3 regulates cell migration independent of EMT in cholangiocarcinoma cells.

Keywords

Acknowledgement

Supported by : Pusan National University Research Grant

References

  1. Anastasiadis PZ, Reynolds AB. (2001). Regulation of Rho GTPases by p120-catenin. Curr Opin Cell Biol 13: 604-610 https://doi.org/10.1016/S0955-0674(00)00258-1
  2. Cheung LW, Leung PC, Wong AS. (2010). Cadherin switching and activation of p120 catenin signaling are mediators of gonadotropin-releasing hormone to promote tumor cell migration and invasion in ovarian cancer. Oncogene 29: 2427-2440 https://doi.org/10.1038/onc.2009.523
  3. Dasgupta S, Tripathi PK, Qin H, Bhattacharya-Chatterjee M, Valentino J, Chatterjee SK. (2006). Identification of molecular targets for immunotherapy of patients with head and neck squamous cell carcinoma. Oral Oncol 42: 306-316 https://doi.org/10.1016/j.oraloncology.2005.08.007
  4. Gamallo C, Moreno-Bueno G, Sarrio D, Calero F, Hardisson D, Palacios J. (2001). The prognostic significance of P-cadherin in infiltrating ductal breast carcinoma. Mod Pathol 14: 650-654 https://doi.org/10.1038/modpathol.3880367
  5. Gorski JJ, James CR, Quinn JE, et al. (2009). BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer. Breast Cancer Res Treat [Epub ahead of print]
  6. Hay E, Nouraud A, Marie PJ. (2009). N-cadherin negatively regulates osteoblast proliferation and survival by antagonizing Wnt, ERK and PI3K/Akt signalling. PLoS One 4: e8284 https://doi.org/10.1371/journal.pone.0008284
  7. Hibi K, Goto T, Mizukami H, et al. (2009a). Demethylation of the CDH3 gene is frequently detected in advanced colorectal cancer. Anticancer Res 29: 2215-2217
  8. Hibi K, Kitamura YH, Mizukami H, et al. (2009b). Frequent CDH3 demethylation in advanced gastric carcinoma. Anticancer Res 29: 3945-3947
  9. Imai K, Hirata S, Irie A, et al. (2008). Identifi cation of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers. Clin Cancer Res 14: 6487-6495 https://doi.org/10.1158/1078-0432.CCR-08-1086
  10. Jeon TY, Han ME, Lee YW, et al. (2010). Overexpression of stathmin1 in the diff use type of gastric cancer and its roles in proliferation and migration of gastric cancer cells. Br J Cancer 102: 710-718 https://doi.org/10.1038/sj.bjc.6605537
  11. Kato I, Kuroishi T, Tominaga S. (1990). Descriptive epidemiology of subsites of cancers of the liver, biliary tract and pancreas in Japan. Jpn J Clin Oncol 20: 232-237
  12. Kinch MS, Clark GJ, Der CJ, Burridge K. (1995). Tyrosine phosphorylation regulates the adhesions of rastransformed breast epithelia. J Cell Biol 130: 461-471 https://doi.org/10.1083/jcb.130.2.461
  13. Milicic A, Harrison LA, Goodlad RA, et al. (2008). Ectopic expression of P-cadherin correlates with promoter hypomethylation early in colorectal carcinogenesis and enhanced intestinal crypt fi ssion in vivo. Cancer Res 68: 7760-7768 https://doi.org/10.1158/0008-5472.CAN-08-0020
  14. Nose A, Takeichi M. (1986). A novel cadherin cell adhesion molecule: its expression patterns associated with implantation and organogenesis of mouse embryos. J Cell Biol 103: 2649-2658 https://doi.org/10.1083/jcb.103.6.2649
  15. Obama K, Ura K, Li M, et al. (2005). Genome-wide anal ysis of gene expression in human intrahepatic cholangiocarcinoma. Hepatology 41: 1339-1348 https://doi.org/10.1002/hep.20718
  16. Olnes MJ, Erlich R. (2004). A review and update on cholangiocarcinoma. Oncology 66: 167-179 https://doi.org/10.1159/000077991
  17. Paredes J, Albergaria A, Oliveira JT, Jeronimo C, Milanezi F, Schmitt FC. (2005). P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res 11: 5869-5877 https://doi.org/10.1158/1078-0432.CCR-05-0059
  18. Paredes J, Correia AL, Ribeiro AS, Milanezi F, Cameselle-Teijeiro J, Schmitt FC. (2008). Breast carcinomas that co-express E- and P-cadherin are associated with p120-catenin cytoplasmic localisation and poor patient survival. J Clin Pathol 61: 856-862 https://doi.org/10.1136/jcp.2007.052704
  19. Pece S, Gutkind JS. (2000). Signaling from E-cadherins to the MAPK pathway by the recruitment and activation of epidermal growth factor receptors upon cell-cell contact formation. J Biol Chem 275: 41227-41233 https://doi.org/10.1074/jbc.M006578200
  20. Peralta Soler A, Knudsen KA, Salazar H, Han AC, Keshgegian AA. (1999). P-cadherin expression in breast carcinoma indicates poor survival. Cancer 86: 1263-1272 https://doi.org/10.1002/(SICI)1097-0142(19991001)86:7<1263::AID-CNCR23>3.0.CO;2-2
  21. Qian X, Karpova T, Sheppard AM, McNally J, Lowy DR. (2004). E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. Embo J 23: 1739-1748 https://doi.org/10.1038/sj.emboj.7600136
  22. Shaib YH, Davila JA, McGlynn K, El-Serag HB. (2004). Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 40: 472-477 https://doi.org/10.1016/j.jhep.2003.11.030
  23. Simpson KJ, Selfors LM, Bui J, et al. (2008). Identification of genes that regulate epithelial cell migration using an siRNA screening approach. Nat Cell Biol 10: 1027-1038 https://doi.org/10.1038/ncb1762
  24. Staddon JM, Smales C, Schulze C, Esch FS, Rubin LL. (1995). p120, a p120-related protein (p100), and the cadherin/catenin complex. J Cell Biol 130: 369-381 https://doi.org/10.1083/jcb.130.2.369
  25. Stefansson IM, Salvesen HB, Akslen LA. (2004). Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol 22: 1242-1252 https://doi.org/10.1200/JCO.2004.09.034
  26. Suyama K, Shapiro I, Guttman M, Hazan RB. (2002). A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell 2: 301-314 https://doi.org/10.1016/S1535-6108(02)00150-2
  27. Takeichi M. (1995). Morphogenetic roles of classic cadherins. Curr Opin Cell Biol 7: 619-627 https://doi.org/10.1016/0955-0674(95)80102-2
  28. Taniuchi K, Nakagawa H, Hosokawa M, et al. (2005). Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases. Cancer Res 65: 3092-3099 https://doi.org/10.1158/0008.5472.CAN-04-3646
  29. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. (1997). Increase in primary liver cancer in the UK, 1979-94. Lancet 350: 1142-1143
  30. Thiery JP, Acloque H, Huang RY, Nieto MA. (2009). Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890 https://doi.org/10.1016/j.cell.2009.11.007
  31. van Roy FM, McCrea PD. (2005). A role for Kaiso-p120ctn complexes in cancer? Nat Rev Cancer 5: 956-964 https://doi.org/10.1038/nrc1752
  32. Yilmaz M, Christofori G. (2009). EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 28: 15-33 https://doi.org/10.1007/s10555-008-9169-0
  33. Zeisberg M, Neilson EG. (2009). Biomarkers for epithelialmesenchymal transitions. J Clin Invest 119: 1429-1437 https://doi.org/10.1172/JCI36183

Cited by

  1. WTAP regulates migration and invasion of cholangiocarcinoma cells vol.48, pp.11, 2013, https://doi.org/10.1007/s00535-013-0748-7
  2. Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker vol.6, pp.None, 2010, https://doi.org/10.1038/srep36138
  3. Initial WNT/β-Catenin Activation Enhanced Mesoderm Commitment, Extracellular Matrix Expression, Cell Aggregation and Cartilage Tissue Yield From Induced Pluripotent Stem Cells vol.8, pp.None, 2010, https://doi.org/10.3389/fcell.2020.581331
  4. Integrative epigenomic profiling reveal AP-1 is a key regulator in intrahepatich cholangiocarcinoma vol.114, pp.1, 2010, https://doi.org/10.1016/j.ygeno.2021.12.008